Europe’s drug patent system: how long protection lasts—and where it quietly breaks down
If you’re building a pipeline, underwriting risk, or pricing a launch strategy, the question isn’t “Do patents exist?” It’s “For how long, in practice, will exclusi…

Drug discovery timelines are getting longer. GPT + Rosalind could be the lever that changes the math.
If you’ve worked anywhere near R&D, you’ve felt it: the clock keeps ticking, budgets tighten, and the “time-to-answer” keeps stretching. In pharma…

The “Patent Expiration Cliff” Isn’t a Cliff—It’s a Calendar. Here’s How Commercial Market Access Teams Can Monetize the Window Before Generics Arrive.
If you’ve ever watched a branded product’s trajectory change overnight—rebates renegotiated, formular…

Authorized Generics: The Innovators’ Playbook for Diluting First-Filer Profits
The first-filer advantage in generic drug launches is often treated like a law of nature: win the patent challenge, capture the early market, and ride the wave of exclusivit…

The clock is ticking—and “generic” isn’t just a product. It’s a timing strategy.
In pharma, everyone talks about exclusivity like it’s a static wall: patents expire, exclusivities end, and then—boom—generic competition arrives. But the real battlegroun…

Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…

Generic competition doesn’t just change prices—it redraws the map of who gets paid.
That’s the real story behind Paragraph IV challenges and pay-for-delay settlements: not “patent wars” as a headline, but a high-stakes transfer of value that can dete…

Consumers don’t usually think in terms of “patent strategy.” But in branded generics, they absolutely pay for it.
Here’s the uncomfortable truth: many people assume a “generic” is just a cheaper version of the same drug. Yet in the real world, branded …

AI is already “reading” your drug—before your competitors do. Here’s what that means for strategy.
In pharma, we’ve spent years building competitive moats around data: clinical packages, manufacturing know-how, regulatory history, patent estates, and t…

Pharma teams are drowning in data—and still making decisions with blind spots.
That’s the uncomfortable truth behind the “intelligence gap” most organizations leave open when they’re trying to read the patent landscape and beat the competition. The res…